Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs
This article was originally published in The Pink Sheet Daily
Probe launched by the Senate Aging panel asks four manufacturers – Valeant, Turing, Retrophin and Rodelis – for documents pertaining to pricing their products, but also wants to know how they may have analyzed FDA regs to help them avoid competition.
You may also be interested in...
In a direct distribution agreement with Walgreens, Valeant, often the focus of criticism over high drug prices, will cut prices 10% on branded dermatology and ophthalmology products and an average of over 50% on certain branded products with generic competition.
Senate Aging Committee hearing addresses generic drug priority reviews at FDA, compounding and publicizing a “watch list” of off-patent drugs with no competition as ways of deterring dramatic price increases for such products.
Senate Special Aging Committee hearing Wednesday to focus on price spikes in off-patent drugs without testimony from drug makers.